Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on June 27, 2007, covering events that occurred on June 26, 2007. The Company is a biotechnology firm incorporated in Florida with principal executive offices in Carmiel, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and market index inclusion rather than financial performance data.
Material Changes
- Board Appointment: The Board of Directors appointed Ms. Yodfat Harel Gross as a director. She was assigned to the Audit Committee and Compensation Committee to serve until the next annual meeting of shareholders.
- Index Inclusion: The Company announced that its shares were added to the broad market Russell 3000(R) Index.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, specific risks, contingencies, or unusual items. The document strictly reports the director appointment and the press release regarding index inclusion.
Investor Verification Checklist
- Verify the effective date of Ms. Yodfat Harel Gross's appointment and her specific committee responsibilities.
- Confirm the impact of Russell 3000(R) Index inclusion on trading volume and institutional ownership.
- Review the attached press release (Exhibit 99.1) for additional details on the index inclusion.